Drug firm MSN Laboratories on Friday said it has entered into a licence agreement with the Defence Research & Development Establishment (DRDE) for the manufacturing, distribution and marketing of 2-Deoxy-D-Glucose (2-DG), used for the treatment of COVID-19.
Developed by DRDO, 2-DG has been granted permission by the Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, MSN Labs said in a statement.
The company has entered into a licence... Читать дальше...